Abstract:Kentaro Nakayama 1 , Sultana Razia 2 , Tomoka Ishibashi 1 , Satoru Kyo 3 1 Department of Obstetrics and Gynecology, Nagoya City University East Medical Center, Nagoya, Japan; 2 Department of Legal Medicine, Shimane University School of Medicine, Izumo, Japan; 3 Department of Obstetrics and Gynecology, Shimane University School of Medicine, Izumo, Japan Comment on: Manning-Geist B, Gordhandas S, Liu YL, et al . MAPK Pathway Genetic Alterations Are Associated with Prolonged Overall Survival in Low-Grade Serous Ovarian Carcinoma. Clin Cancer Res 2022;28:4456-65. Keywords: Genetic alterations; low-grade serous ovarian carcinoma (LGSOC); MAPK pathway; molecular targeted therapy; overall survival (OS) Submitted Jul 07, 2023. Accepted for publication Dec 14, 2023. Published online Jan 25, 2024. doi: 10.21037/tcr-23-1161 Epithelial ovarian cancer (EOC) is responsible for more than 14,070 mortalities annually worldwide, making it the third most lethal malignancy affecting the female reproductive tract (1). Despite the significant advances in early diagnostic techniques, surgical techniques, and adjuvant therapy for ovarian cancer, the prognosis has remained unchanged for over 50 years. The significant postoperative prognostic factors include age, disease stage, performance status, histological subtype, tumor grade, and the extent of residual tumors (2). Among them, recognizing the histological subtypes is crucial for developing new treatment approaches due to their distinct molecular profiles. Recently, clinical, pathological, and molecular data have suggested that EOC can be broadly categorized into two subgroups as follows: types I and II (3). High-grade serous carcinomas (HGSOCs) are predominantly classified as type II tumors, representing the most common type of epithelial carcinoma, which is characterized by aggressive behaviors. Type I tumors include low-grade serous carcinoma (LGSOCs) and endometrioid, mucinous, and clear cell carcinomas. LGSOCs are relatively rare, typically diagnosed in younger women, and account for <5% of all ovarian carcinoma cases. The average age at diagnosis for LGSOCs is 55.5 years, which is significantly lower than the average age of 62.6 years for HGSOCs (4). A median age of 45 years has also been reported in several publications. LGSOCs can affect women of all ages, with reported cases occurring between the ages of nineteen and 79 years. They are believed to originate from serous cystadenomas or adenofibromas through a sequential and indolent process. These precursor lesions subsequently progress into serous borderline tumors (SBTs), which are characterized by invasive or non-invasive implants. SBTs progress to their full pathological potential over time and manifest as LGSOCs. Although the pathological development is generally considered to be sequential, rare instances exist where certain stages of the sequence may be skipped, leading to direct progression from a classic SBT to LGSOCs. Generally, LGSOCs are characterized by a higher likelihood of survival and are considered less aggressive than HGSOCs. However, they can experience instances of multiple recurrences and may exhibit reduced sensitivity to chemotherapy (4). Despite the slow growth pattern of LGSOCs, their tendency to be diagnosed at an advanced stage and resistance to standard systemic therapies ultimately contribute to the high fatality rate associated with this subtype. LGSOCs exhibit significant resistance to chemotherapy, and no established treatment is currently tailored for LGSOCs compared with HGSOCs. LGSOCs and HGSOCs exhibit different molecular and genetic features at the molecular level. Molecular biology investigations have identified the activation of the mitogen-activated protein kinase (MAPK) signaling pathway and the higher expression of estrogen receptors (ERs) (approximately 80.7%) and progestogen receptors (PRs) (approximately 54.4%) as factors involved in the pathogenesis of LGSOCs (5-7). HGSOCs are also characterized by widespread p53 mutations, elevated chromosomal instability, and germline alterations in the genes involved in homologous recombination repair, including BRCA1/2 (8). Numerous studies have reported a wide range of mutation frequencies in LGSOCs. Specifically, the prevalence of KRAS mutations in LGSOCs reportedly ranged from 16% to 44%, BRAF mutations from 2% to 20%, and NRAS mutations up to 26% in Western countries (6,7). Furthermore, alterations within the MAPK pathway have also been implicated in 60–82% of LGSOC cases (9,10). Among patients experiencing recurrences, KRAS hotspot mutations were the most common alterations, accounting for 33% of cases, followed by BRAF and NRAS alterations in 11% and 11%, respectively. Notably, these muta -Abstract Truncated-

Exploring novel approaches in the systemic therapy of low-grade serous carcinoma of the ovary: a literature review

Low Grade Serous Ovarian Carcinoma: from the molecular characterization to the best therapeutic strategy

Novel Targeted Agents in Advanced and Recurrent Low-Grade Serous Ovarian Cancer: A Silver Lining in the Therapy of a Chemoresistant Disease?

Advances in precision therapy of low-grade serous ovarian cancer: A review

Targeted Therapies in Low-Grade Serous Ovarian Cancers

Clinical parameters affecting survival outcomes in patients with low-grade serous ovarian carcinoma: an international multicentre analysis

The Role of Systematic Lymphadenectomy in Low-Grade Serous Ovarian Cancer: A Systematic Review and Meta-Analysis

Novel Endocrine Therapeutic Opportunities for Estrogen Receptor-Positive Ovarian Cancer—What Can We Learn from Breast Cancer?

Targeted therapy in high grade serous ovarian Cancer: A literature review

Changes in the tumour microenvironment mark the transition from serous borderline tumour to low-grade serous carcinoma

Bevacizumab Treatment for Low-Grade Serous Ovarian Cancer: A Systematic Review

A Comprehensive Review of Ovarian Cancer Management in an Era of Advancements

High-throughput drug screening identifies novel therapeutics for Low Grade Serous Ovarian Carcinoma

Expression of hypothalamic-pituitary-gonadal axis-related hormone receptors in low-grade serous ovarian cancer (LGSC)

Folate receptor alpha expression in low-grade serous ovarian cancer: Exploring new therapeutic possibilities

Prognostic And Therapeutic Factors For Low-Grade Serous Ovarian Carcinoma: A Multicentric, Retrospective Study Of The Turkish Society Of Gynaecologic Oncology

Current concept of low-grade serous ovarian carcinoma

Low-Grade Serous Ovarian Cancer: Expert Consensus Report on the State of the Science

New Achievements from Molecular Biology and Treatment Options for Refractory/Relapsed Ovarian Cancer—A Systematic Review

High-Grade Serous Ovarian Cancer: Basic Sciences, Clinical and Therapeutic Standpoints

Somatic genomic and transcriptomic characterization of primary ovarian serous borderline tumors and low-grade serous carcinomas.